AU2623800A - Pyroglutamic acid derivatives and related compounds which inhibit leukocyte adhesion mediated by vla-4 - Google Patents

Pyroglutamic acid derivatives and related compounds which inhibit leukocyte adhesion mediated by vla-4

Info

Publication number
AU2623800A
AU2623800A AU26238/00A AU2623800A AU2623800A AU 2623800 A AU2623800 A AU 2623800A AU 26238/00 A AU26238/00 A AU 26238/00A AU 2623800 A AU2623800 A AU 2623800A AU 2623800 A AU2623800 A AU 2623800A
Authority
AU
Australia
Prior art keywords
vla
acid derivatives
related compounds
pyroglutamic acid
leukocyte adhesion
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Abandoned
Application number
AU26238/00A
Other languages
English (en)
Inventor
Darren B. Dressen
Anthony Kreft
Dennis Kubrak
Charles William Mann
Michael A. Pleiss
Gary Paul Stack
Eugene D. Thorsett
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Wyeth LLC
Elan Pharmaceuticals LLC
Original Assignee
Elan Pharmaceuticals LLC
American Home Products Corp
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Elan Pharmaceuticals LLC, American Home Products Corp filed Critical Elan Pharmaceuticals LLC
Publication of AU2623800A publication Critical patent/AU2623800A/en
Abandoned legal-status Critical Current

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K5/00—Peptides containing up to four amino acids in a fully defined sequence; Derivatives thereof
    • C07K5/04—Peptides containing up to four amino acids in a fully defined sequence; Derivatives thereof containing only normal peptide links
    • C07K5/06—Dipeptides
    • C07K5/06139—Dipeptides with the first amino acid being heterocyclic
    • C07K5/06173—Dipeptides with the first amino acid being heterocyclic and Glp-amino acid; Derivatives thereof
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/04—Drugs for disorders of the alimentary tract or the digestive system for ulcers, gastritis or reflux esophagitis, e.g. antacids, inhibitors of acid secretion, mucosal protectants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00—Drugs for disorders of the respiratory system
    • A61P11/06—Antiasthmatics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P13/00—Drugs for disorders of the urinary system
    • A61P13/12—Drugs for disorders of the urinary system of the kidneys
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00—Drugs for dermatological disorders
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00—Drugs for dermatological disorders
    • A61P17/06—Antipsoriatics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P27/00—Drugs for disorders of the senses
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/08—Drugs for disorders of the metabolism for glucose homeostasis
    • A61P3/10—Drugs for disorders of the metabolism for glucose homeostasis for hyperglycaemia, e.g. antidiabetics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A61P35/04—Antineoplastic agents specific for metastasis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K5/00—Peptides containing up to four amino acids in a fully defined sequence; Derivatives thereof
    • C07K5/04—Peptides containing up to four amino acids in a fully defined sequence; Derivatives thereof containing only normal peptide links
    • C07K5/06—Dipeptides
    • C07K5/06139—Dipeptides with the first amino acid being heterocyclic
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K5/00—Peptides containing up to four amino acids in a fully defined sequence; Derivatives thereof
    • C07K5/04—Peptides containing up to four amino acids in a fully defined sequence; Derivatives thereof containing only normal peptide links
    • C07K5/06—Dipeptides
    • C07K5/06139—Dipeptides with the first amino acid being heterocyclic
    • C07K5/06165—Dipeptides with the first amino acid being heterocyclic and Pro-amino acid; Derivatives thereof
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K5/00—Peptides containing up to four amino acids in a fully defined sequence; Derivatives thereof
    • C07K5/04—Peptides containing up to four amino acids in a fully defined sequence; Derivatives thereof containing only normal peptide links
    • C07K5/06—Dipeptides
    • C07K5/06191—Dipeptides containing heteroatoms different from O, S, or N

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Public Health (AREA)
  • Animal Behavior & Ethology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Veterinary Medicine (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Biochemistry (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Molecular Biology (AREA)
  • Genetics & Genomics (AREA)
  • Biophysics (AREA)
  • Diabetes (AREA)
  • Neurology (AREA)
  • Dermatology (AREA)
  • Urology & Nephrology (AREA)
  • Pulmonology (AREA)
  • Biomedical Technology (AREA)
  • Neurosurgery (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Emergency Medicine (AREA)
  • Psychiatry (AREA)
  • Pain & Pain Management (AREA)
  • Rheumatology (AREA)
  • Oncology (AREA)
  • Obesity (AREA)
  • Cardiology (AREA)
  • Vascular Medicine (AREA)
  • Hospice & Palliative Care (AREA)
  • Endocrinology (AREA)
  • Hematology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
AU26238/00A 1999-01-26 2000-01-21 Pyroglutamic acid derivatives and related compounds which inhibit leukocyte adhesion mediated by vla-4 Abandoned AU2623800A (en)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US23866199A 1999-01-26 1999-01-26
US09238661 1999-01-26
PCT/US2000/001537 WO2000043413A2 (en) 1999-01-26 2000-01-21 Pyroglutamic acid derivatives and related compounds which inhibit leukocyte adhesion mediated by vla-4

Publications (1)

Publication Number Publication Date
AU2623800A true AU2623800A (en) 2000-08-07

Family

ID=22898814

Family Applications (1)

Application Number Title Priority Date Filing Date
AU26238/00A Abandoned AU2623800A (en) 1999-01-26 2000-01-21 Pyroglutamic acid derivatives and related compounds which inhibit leukocyte adhesion mediated by vla-4

Country Status (12)

Country Link
EP (2) EP1612215A1 (de)
JP (1) JP2002535341A (de)
CN (1) CN1195773C (de)
AR (1) AR022405A1 (de)
AT (1) ATE323102T1 (de)
AU (1) AU2623800A (de)
CA (1) CA2358093A1 (de)
DE (1) DE60027268T2 (de)
ES (1) ES2262504T3 (de)
HK (1) HK1046146B (de)
TW (1) TWI224110B (de)
WO (1) WO2000043413A2 (de)

Families Citing this family (10)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CA2358093A1 (en) * 1999-01-26 2000-07-27 Elan Pharmaceuticals, Inc. Pyroglutamic acid derivatives and related compounds which inhibit leukocyte adhesion mediated by vla-4
US6407066B1 (en) * 1999-01-26 2002-06-18 Elan Pharmaceuticals, Inc. Pyroglutamic acid derivatives and related compounds which inhibit leukocyte adhesion mediated by VLA-4
JP5401218B2 (ja) * 2009-09-03 2014-01-29 東京応化工業株式会社 レジスト組成物、レジストパターン形成方法
CN108299218A (zh) * 2017-01-12 2018-07-20 南京红杉生物科技有限公司 一种4-溴-d-苯丙氨酸的合成方法
CN109180552B (zh) * 2018-09-26 2021-10-26 沈阳药科大学 取代的5-氧代吡咯烷类衍生物及其制备方法和应用
CN112969700A (zh) 2018-10-30 2021-06-15 吉利德科学公司 作为α4β7整合素抑制剂的咪唑并吡啶衍生物
CN112969687A (zh) 2018-10-30 2021-06-15 吉利德科学公司 作为α4β7整合素抑制剂的喹啉衍生物
EP3873897A1 (de) 2018-10-30 2021-09-08 Gilead Sciences, Inc. Verbindungen zur inhibierung von alpha-4-beta-7-integrin
JP7189369B2 (ja) 2018-10-30 2022-12-13 ギリアード サイエンシーズ， インコーポレイテッド アルファ４β７インテグリンの阻害のための化合物
WO2021030438A1 (en) 2019-08-14 2021-02-18 Gilead Sciences, Inc. Compounds for inhibition of alpha 4 beta 7 integrin

Family Cites Families (5)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
AU2964295A (en) * 1994-07-11 1996-02-09 Athena Neurosciences, Inc. Inhibitors of leukocyte adhesion
DK0910575T3 (da) * 1996-06-21 2003-02-03 Takeda Chemical Industries Ltd Fremgangsmåde til fremstilling af peptider
PL338373A1 (en) * 1997-07-31 2000-10-23 Elan Pharm Inc Dipeptide and its affinite compounds inhibiting adhesion of leucocytes occurring through mediation of vla-4
TW591026B (en) * 1998-06-23 2004-06-11 Upjohn Co Inhibitors of alpha4beta1 mediated cell adhesion
CA2358093A1 (en) * 1999-01-26 2000-07-27 Elan Pharmaceuticals, Inc. Pyroglutamic acid derivatives and related compounds which inhibit leukocyte adhesion mediated by vla-4

Also Published As

Publication number Publication date
EP1144435A2 (de) 2001-10-17
EP1612215A1 (de) 2006-01-04
TWI224110B (en) 2004-11-21
AR022405A1 (es) 2002-09-04
HK1046146A1 (en) 2002-12-27
DE60027268T2 (de) 2007-03-15
JP2002535341A (ja) 2002-10-22
CA2358093A1 (en) 2000-07-27
DE60027268D1 (de) 2006-05-24
WO2000043413A2 (en) 2000-07-27
CN1344274A (zh) 2002-04-10
ATE323102T1 (de) 2006-04-15
HK1046146B (zh) 2005-07-29
EP1144435B1 (de) 2006-04-12
CN1195773C (zh) 2005-04-06
WO2000043413A3 (en) 2000-11-30
ES2262504T3 (es) 2006-12-01

Similar Documents

Publication Publication Date Title
AU2623900A (en) Compounds which inhibit leukocyte adhesion mediated by vla-4
HK1045157A1 (zh) 抑制vla-4介導的白細胞粘着的化合物
AU2730600A (en) Medical adhesives
HUP0004259A3 (en) Substituted phenylalanine type compounds which inhibit leukocyte adhesion mediated by vla-4, pharmaceutical compositions comprising thereof
AU5152100A (en) Substituted beta-alanine derivatives as cell adhesion inhibitors
HUP0004531A3 (en) 4-amino-phenylalanine type compounds which inhibit leukocyte adhesion mediated by vla-4, pharmaceutical compositions comprising thereof and their use
IL133641A0 (en) Compounds which inhibit leukocyte adhesion mediated by vla-4
AU7389300A (en) Methods of administration of glycopyrrolate compositions
HUP0002495A3 (en) Dipeptide and related compounds which inhibit leukocyte adhesion mediated by vla-4, pharmaceutical compositions comprising thereof and their use
AU3348800A (en) Multicyclic compounds which inhibit leukocyte adhesion mediated by vla-4
AU1998100A (en) Novel curative for anaerobic adhesive compositions
AU2623399A (en) 3-hydroxy-4-aryl-5-pyrazoline derivatives as herbicides
AU2623800A (en) Pyroglutamic acid derivatives and related compounds which inhibit leukocyte adhesion mediated by vla-4
AU2001276022A1 (en) Beta-amino acid derivatives-inhibitors of leukocyte adhesion mediated by vla-4
AU5429000A (en) Novel bicyclonucleoside derivatives
AU3670000A (en) Novel thiazolobenzimidazole derivatives
AU2199401A (en) Propanoic acid derivatives as integrin inhibitors
AUPQ441499A0 (en) Novel compound
AU5460800A (en) Pharmaceutical transdermal compositions
AU7961300A (en) Kainic acid neurocytotoxicity inhibitors
AU5231900A (en) Adhesive tapes
AU2001282938A1 (en) Alpha amino acid derivatives--inhibitors of leukocyte adhesion mediated by vla-4
AU1303201A (en) Alkoxyiminoalkanoic acid derivatives
AUPQ365299A0 (en) Anthranilic acid derivatives
AU3348700A (en) Compounds which inhibit leukocyte adhesion mediated by vla-4

Legal Events

Date Code Title Description
MK6 Application lapsed section 142(2)(f)/reg. 8.3(3) - pct applic. not entering national phase